Abstract:Our purpose was to prospectively assess the distribution of NETPET scores in well-differentiated (WD) grade 2 and 3 gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and to determine the impact of the NETPET score on clinical management. Methods: This single-arm, institutional ethics review board–approved prospective study included 40 patients with histologically proven WD GEP NETs. 68 Ga-DOTATATE PET and 18 F-FDG PET were performed within 21 d of each other. NETPET scores were evaluated qualitatively by 2 reviewers, with up to 10 marker lesions selected for each patient. The quantitative parameters that were evaluated included marker lesion SUV max for each tracer; 18 F-FDG/ 68 Ga-DOTATATE SUV max ratios; functional tumor volume (FTV) and metabolic tumor volume (MTV) on 68 Ga-DOTATATE and 18 F-FDG PET, respectively; and FTV/MTV ratios. The treatment plan before and after 18 F-FDG PET was recorded. Results: There were 22 men and 18 women (mean age, 60.8 y) with grade 2 ( n = 24) or grade 3 ( n = 16) tumors and a mean Ki-67 index of 16.1%. NETPET scores of P0, P1, P2A, P2B, P3B, P4B, and P5 were documented in 2 (5%), 5 (12.5%), 5 (12.5%) 20 (50%), 2 (5%), 4 (10%), and 2 (5%) patients, respectively. No association was found between the SUV max of target lesions on 68 Ga-DOTATATE and the SUV max of target lesions on 18 F-FDG PET ( P = 0.505). 18 F-FDG/ 68 Ga-DOTATATE SUV max ratios were significantly lower for patients with low (P1–P2) primary NETPET scores than for those with high (P3–P5) primary NETPET scores (mean ± SD, 0.20 ± 0.13 and 1.68 ± 1.44, respectively; P < 0.001). MTV on 18 F-FDG PET was significantly lower for low primary NETPET scores than for high ones (mean ± SD, 464 ± 601 cm 3 and 66 ± 114 cm 3 , respectively; P = 0.005). A change in the type of management was observed in 42.5% of patients after 18 F-FDG PET, with the most common being a change from systemic therapy to peptide receptor radionuclide therapy and from debulking surgery to systemic therapy. Conclusion: There was a heterogeneous distribution of NETPET scores in patients with WD grade 2 and 3 GEP NETs, with more than 1 in 5 patients having a high NETPET score and a frequent change in management after 18 F-FDG PET. Quantitative parameters including 18 F-FDG/ 68 Ga-DOTATATE SUV max ratios in target lesions and FTV/MTV ratios can discriminate between patients with high and low NETPET scores.

False-Negative Neuroendocrine Tumor Identified With 68 Ga-DOTATOC PET/CT : A Case of Well-Differentiated Somatostatinoma

A False-Negative 123I-MIBG SPECT/CT With True-Positive 68Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177Lu-DOTATATE Therapy

Heterogenous Uptake of 68Ga-Dotatate and 18F-FDG in Patients with Initially Diagnosed Neuroendocrine Tumors: Which Patients Are Suitable for Dual-Tracer PET Imaging?

Fibromatosis mimicking relapse of a neuroendocrine tumor at 68Ga-DOTATOC positron-emission tomography/computed tomography

False-Negative 68Ga-FAPI PET/CT in Pediatric Thyroid Medullary Carcinoma Seen With 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT

[Malignant Tumor with False Negative 18F-FDG PET Image].

Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1

68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer

A Rare Case of Neuroendocrine Prostate Cancer Detected on 68Ga - DOTANOC Positron Emission Tomography/Computed Tomography (PET/CT)

False Positive Findings of [18F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels

Somatostatin Receptor Imaging with [18F]FET-{beta}AG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study

Humongous Seminal Vesicles on 68Ga-DOTATOC PET/CT: A Rare Presentation of a Neuroendocrine Tumor

False-Positive Asymmetrical Tongue Muscle 18F-FDG Uptake in Hypoglossal Nerve Paralysis Following Lymph Node Dissection in a Pediatric Patient with Malignant Rhabdoid Tumor of the Neck

Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours

Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient

Fine needle aspiration diagnosis of benign oncocytic lesions of the head and neck associated with false positive 18F-fluorodeoxyglucose uptake on positron emission tomography scan

Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors

Novel Detection of Pleomorphic Adenomas via Analysis of 68Ga-DOTATOC PET/CT Imaging

Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT

Identification of Wandering Masses and Tumor Heterogeneity on 68Ga-DOTATATE and 18F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT

Comparison of [ 18 F]-OC PET/CT and Contrast-Enhanced CT/MRI in the Detection and Evaluation of Neuroendocrine Neoplasms